THE LANCET
Haematology

COMMENT | ONLINE FIRST

Will the changing therapeutic landscape meet the needs of patients with sickle cell disease?

Baba Psalm Duniya Inusa • Maddalena Casale • Andrew Campbell • Natasha Archer

Published: April 07, 2021 • DOI: https://doi.org/10.1016/S2352-3026(21)00098-3 •

In *The Lancet Haematology,* Jo Howard and colleagues [1] report the end of study results of the international, randomised, double-blind, placebo-controlled, phase 3 HOPE trial. The manuscript focuses on the study's long-term activity endpoint, including the proportion of patients with a haemoglobin response (defined as the proportion of patients who had a haemoglobin change from baseline of >1 g/dL) at week 72; the results for this endpoint at week 24 were published in a previous report in 2019. [2]

References

1. Howard J • Ataga KI • Brown RC • et al.
Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Haematol. 2021; (published online April 7.)
https://doi.org/10.1016/S2352-3026(21)00059-4

View in Article
Google Scholar

2. Vichinsky E • Hoppe CC • Ataga KI • et al.
A phase 3 randomized trial of voxelotor in sickle cell disease.
N Engl J Med. 2019; **381**: 509-519

View in Article
Scopus (86) • PubMed • Crossref • Google Scholar

3. Pauling L • Itano HA • Singer SJ • Wells IC
Sickle cell anemia a molecular disease.
Science. 1949; **110**: 543-548

View in Article
PubMed • Crossref • Google Scholar

4. Ingram VM
A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin.
Nature. 1956; **178**: 792-794

View in Article
Scopus (434) • PubMed • Crossref • Google Scholar

5. Platt OS
ɔxyurea for the treatment of sickle cell anemia.
ɡl J Med. 2008; **358**: 1362-1369

View in Article

Scopus (229) • PubMed • Crossref • Google Scholar

6. Hebbel RP • Hedlund BE
Sickle hemoglobin oxygen affinity-shifting strategies have unequal cerebrovascular risks.
Am J Hematol. 2018; **93**: 321-325

View in Article

Scopus (14) • PubMed • Crossref • Google Scholar

7. Dufu K • Lucas A • Rodrigues Muller C • et al.
Pharmacological increase of Hb-O_2 affinity with a voxelotor analog does not decrease brain tissue pO_2 or limit O_2 extraction in brain tissues of sickle cell mice.
Blood. 2019; **134** (abstr).3564

View in Article

Crossref • Google Scholar

8. Estepp JH • Wang W • Hwang S • Hillenbrand C • Ogg R
Cerebral blood flow in adolescents with sickle cell anemia receiving voxelotor.
Hemasphere. 2019; **3** (abstr).: 324

View in Article

Crossref • Google Scholar

9. Ataga KI • Gordeuk VR • Agodoa I • Colby JA • Gittings K • Allen IE
Low hemoglobin increases risk for cerebrovascular disease, kidney disease, pulmonary vasculopathy, and mortality in sickle cell disease: a systematic literature review and meta-analysis.
PLoS One. 2020; **15**e0229959

View in Article

Scopus (0) • PubMed • Crossref • Google Scholar

Article Info

ıtion History

ıed: April 07, 2021

Identification

DOI: https://doi.org/10.1016/S2352-3026(21)00098-3

Copyright

ScienceDirect

Access this article on ScienceDirect

Linked Articles

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial

- Full-Text
- PDF

THE LANCET

LANCET JOURNALS

The Lancet

The Lancet Child & Adolescent Health

The Lancet Diabetes & Endocrinology

The Lancet Digital Health

The Lancet Gastroenterology & Hepatology

The Lancet Global Health

The Lancet Haematology

The Lancet Healthy Longevity

ancet HIV

The Lancet Infectious Diseases

The Lancet Microbe

The Lancet Neurology

The Lancet Oncology

The Lancet Planetary Health

The Lancet Psychiatry

The Lancet Public Health

The Lancet Regional Health – Americas

The Lancet Regional Health – Europe

The Lancet Regional Health – Western Pacific

The Lancet Respiratory Medicine

The Lancet Rheumatology

EBioMedicine

EClinicalMedicine

CLINICAL INITIATIVES

The *Lancet* Clinic

Commissions

Series

Picture Quiz

GLOBAL HEALTH INITIATIVES

Global Health Portal

Commissions

Series

Global Burden of Disease

Climate Countdown

MEDIA

Infographics

Podcasts

Videos

INFORMATION

About us

For authors

For advertisers

For press

Publishing excellence

Careers

Conferences

ACCESS

Access our content

Register an account

My account

Personal subscriptions

Open Access

Existing print subscribers

Request institutional access

CONNECT

Lancet alerts

Contact us

Customer service